T-26 Impact of anemia and ribavirin dose reduction on SVR to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the Phase III REALIZE study
Title:
T-26 Impact of anemia and ribavirin dose reduction on SVR to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the Phase III REALIZE study
Author:
Andreone, P. Roberts, S. Pol, S. Younossi, Z. Diago, M. Lawitz, E.J. Focaccia, R. Foster, G.R. Horban, A. Lonjon-Domanec, I. DeMasi, R. Van Heeswijk, R. Picchio, G. Witek, J. Zeuzem, S.